Differential-reinforcement-of-low-rate-schedule performance and nicotine administration: a systematic investigation of dose, dose-regimen, and schedule requirement.
Differential-reinforcement-of-low-rate (DRL) schedules have been used to evaluate the effects of a wide variety of drugs, including amphetamines, cannabinoids, and antidepressant medication. To earn a reinforcer, organisms operating under a DRL schedule are required to withhold a response for a predetermined amount of time before responding, and therefore this schedule maintains a low rate of responding and can be viewed as a response-inhibition task. In experiment 1, three different DRL schedules (4.5, 9.5, and 29.5 s) were used to evaluate systematically a range of nicotine doses (0.0, 0.1, 0.3, and 0.5 mg/kg). The dose-response effect of nicotine then was compared with the effects of increased reinforcer magnitude on responding. Both the administration of nicotine and increased reinforcer magnitude engendered less accurate DRL-schedule performance compared with baseline conditions, and the dose and magnitude-dependent shifts were most evident on the DRL 29.5-s schedule. Experiment 2 compared the differences between acute and chronic dosing regimens (0.3 mg/kg nicotine) on DRL 29.5-s schedule responding. After 20 consecutive sessions of nicotine dosing, accuracy deteriorated significantly, demonstrating that chronic nicotine dosing leads to a behavioral sensitization apparent on the DRL 29.5-s schedule. The results from both experiments suggest that responding on the DRL 29.5-s schedule is sensitive to both dose-response and regimen-dependent effects of nicotine.
Kirshenbaum
Ari P
AP
Psychology Department, Psychopharmacology Laboratory, Saint Michael's College, One Winooski Park, Colchester, Vermont, USA. akirshenbaum@smcvt.edu
Brown
Seth J
SJ
Hughes
David M
DM
Doughty
Adam H
AH
D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D007266:Inhibition, Psychological; D007279:Injections, Subcutaneous; D008297:Male; D009042:Motivation; D009538:Nicotine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012055:Reinforcement Schedule; D013998:Time Perception / Q000187:drug effects; D014029:Tobacco Use Disorder / Q000523:psychology*
D009538:Nicotine
Pharmacol Biochem Behav. 2000 Feb;65(2):247-54
10672976
Behav Brain Res. 2002 Dec 2;137(1-2):75-114
12445717
J Exp Anal Behav. 1961 Oct;4:327-30
13909599
J Exp Anal Behav. 1965 Jan;8:19-27
14266504
Psychopharmacology (Berl). 2006 Nov;189(1):27-36
17019569
Can J Psychol. 1964 Dec;18:321-7
14258395
Q J Exp Psychol (Hove). 2006 Apr;59(4):625-53
16707354
Addiction. 2001 Jan;96(1):103-14
11177523
Eur J Neurosci. 2005 Nov;22(10):2605-16
16307603
Psychopharmacology (Berl). 2002 Sep;163(2):230-7
12202970
Psychopharmacology (Berl). 1999 Oct;146(4):348-61
10550486
Behav Pharmacol. 2005 Feb;16(1):15-23
15706134
J Exp Anal Behav. 1985 May;43(3):407-17
16812421
Psychopharmacology (Berl). 1997 Oct;133(3):207-13
9361325
J Exp Psychol Anim Behav Process. 2004 Jan;30(1):3-16
14709111
J Exp Anal Behav. 2002 Jul;78(1):17-30
12144310
Psychopharmacology (Berl). 2004 Apr;173(1-2):98-104
14727001
Behav Pharmacol. 1997 Aug;8(4):293-308
9832989
Neuropharmacology. 1970 Jan;9(1):9-16
5426758
J Exp Anal Behav. 2007 Mar;87(2):201-18
17465312
Behav Brain Res. 2001 Jun;121(1-2):137-47
11275291
Curr Opin Pharmacol. 2007 Feb;7(1):69-76
17174602
Addiction. 2001 Jan;96(1):73-86
11177521
Psychopharmacology (Berl). 2003 Aug;169(1):68-76
12774186
Psychopharmacology (Berl). 1999 Oct;146(4):373-90
10550488
J Exp Anal Behav. 1993 Sep;60(2):361-85
8409824
Psychopharmacologia. 1968;12(2):176-80
5657051
J Neurosci. 2002 Apr 15;22(8):3269-76
11943828
Pharmacol Biochem Behav. 1997 Jul;57(3):513-21
9218276
J Pharmacol Exp Ther. 1997 Jun;281(3):1368-80
9190873
Psychopharmacology (Berl). 2004 Jan;171(2):173-8
13680077
Neuropsychologia. 2002;40(10):1675-89
11992656